US equities |
MU $928.76 ▲+0.00% SNDK $1,304.84 ▲+0.00% SKHY $145.36 ▲+0.00% TSLA $407.46 ▲+0.00% NVDA $217.94 ▲+0.00% INTC $93.74 ▲+0.00% GOOGL $320.58 ▲+0.00% SPCX $148.58 ▲+0.00%
FinancialContent

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

15.33 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,786
Open 15.33
Bid (Size) 15.30 (100)
Ask (Size) 15.60 (300)
Prev. Close 15.33
Today's Range 15.33 - 15.33
52wk Range 12.07 - 29.23
Shares Outstanding 97,381,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts ↗
MercadoLibre, Novo Nordisk, Tyler Technologies and Summit Therapeutics trade below recent highs, yet each has earnings or catalysts that could shift sentiment. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China
From Summit Therapeutics
Via Business Wire

Performance

52-Week Range 47.6% below 52-week high
15.33
12.0752W Low 29.2352W High
1 Week 6.2% below 1-week high
14.371W Low 16.351W High

Summit Therapeutics Inc. - Common Stock (SMMT) traded between $12.07 and $29.23 over the past 52 weeks and last traded at $15.33, 47.6% below its 52-week high. Over the past week it ranged between $14.37 and $16.35.

Past 12 Months
-3.2%
-1.0%
+22.2%
-27.9%
-12.5%
-21.2%
1W -$0.50
1M -$0.15
3M +$2.78
6M -$5.93
YTD -$2.19
1Y -$4.13

SMMT was -21.2% over the past year, -27.9% over six months, -12.5% year to date, -3.2% in the last week.

12 Months vs Market
SMMT
-21.2%
DIA
+10.1%
SPY
+12.3%
QQQ
+14.8%
IWM
+11.9%

Over the past 12 months SMMT returned -21.2% versus DIA (Dow) +10.1%, SPY (S&P 500) +12.3%, QQQ (Nasdaq 100) +14.8% and IWM (Russell 2000) +11.9%.

Volume & Liquidity 0.00× 3-mo avg
Today 6,786 3-mo avg 6.1M
1W
4.5M
1M
6.9M
3M
6.1M
6M
5.7M
YTD
4.6M
1Y
4.2M

SMMT most recently traded 6,786 shares against a 3-month average daily volume of 6.1M.

More News

Read More
News headline image
Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
From Summit Therapeutics
Via Business Wire
Summit Therapeutics (SMMT) Reports In-Line Q2 Loss; Stock Eases Amid Pivotal PDUFA Catalyst ↗
Via Chartmill
News headline image
Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma
From Summit Therapeutics
Via Business Wire
News headline image
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
From Summit Therapeutics
Via Business Wire
These stocks that are showing activity before the opening bell on Tuesday. ↗
Via Chartmill
News headline image
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
From Summit Therapeutics
Via Business Wire
News headline image
HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026
From Summit Therapeutics
Via Business Wire
News headline image
Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients
From Summit Therapeutics
Via Business Wire
News headline image
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China
From Summit Therapeutics
Via Business Wire
News headline image
Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China
From Summit Therapeutics
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
From Summit Therapeutics
Via Business Wire
News headline image
Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
From Summit Therapeutics
Via Business Wire
News headline image
GLP-1 Drugs Are Huge. These 2 Stocks Are Tapping Into an Even Bigger Opportunity ↗
Via The Motley Fool
News headline image
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
From Summit Therapeutics
Via Business Wire
News headline image
Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
From Summit Therapeutics
Via Business Wire

Frequently Asked Questions

Is Summit Therapeutics Inc. - Common Stock publicly traded?
Yes, Summit Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Summit Therapeutics Inc. - Common Stock trade on?
Summit Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Summit Therapeutics Inc. - Common Stock?
The ticker symbol for Summit Therapeutics Inc. - Common Stock is SMMT on the Nasdaq Stock Market
What is the current price of Summit Therapeutics Inc. - Common Stock?
The current price of Summit Therapeutics Inc. - Common Stock is 15.33
When was Summit Therapeutics Inc. - Common Stock last traded?
The last trade of Summit Therapeutics Inc. - Common Stock was at 10/27/26 04:00 PM ET
What is the market capitalization of Summit Therapeutics Inc. - Common Stock?
The market capitalization of Summit Therapeutics Inc. - Common Stock is 1.49B
How many shares of Summit Therapeutics Inc. - Common Stock are outstanding?
Summit Therapeutics Inc. - Common Stock has 1B shares outstanding.